Optimal - multimillion/billions worth of value to Pharma20 Mar 2025 08:53
The Raise is to capitalise on the remarkable opportunity optimal presents.
Some thoughts from Chat GPT research on the potential value here:
“ A big pharma company could place significant value on the OptiMAL antibody discovery platform due to its potential to accelerate drug discovery, reduce manufacturing risks, and improve clinical success rates. Traditional discovery methods can take months or years, but OptiMAL’s high-throughput mammalian display could potentially cut this timeline in half, providing a critical competitive advantage in launching biologics ahead of rivals. Given that blockbuster antibody drugs generate $1B–$5B per year, even a 6–12 month acceleration could be worth hundreds of millions of dollars in additional revenue.
Beyond speed, the manufacturability-first approach could prevent costly failures later in development, where attrition rates are notoriously high. Late-stage clinical failures due to poor expression or immunogenicity can cost $100M–$500M per candidate, and avoiding just one failure would justify a substantial investment in the platform. If OptiMAL improves the probability of clinical success by even 5%, it could save pharma companies hundreds of millions in wasted R&D and increase the number of successful drugs in their portfolio.
From a commercial standpoint, a large pharma company might see multiple strategic opportunities with OptiMAL, whether through exclusive licensing, milestone-based partnerships, or even outright acquisition. A licensing deal could be worth $10M–$50M upfront, plus $50M–$200M in milestones per successful drug, and 5–10% royalties on future sales. If a single blockbuster antibody comes out of the platform, the total value could exceed $500M–$1B. Given the industry’s increasing focus on biologics, OptiMAL could be seen as a highly valuable asset, either as a proprietary advantage or a disruptive force in antibody discovery.”
Sign In
Follow the stocks
